Sevigny, Jeff
F. Hoffmann-La Roche AG
4 papers on CoChatORCID 0000-0003-0974-6434
Most cited papers
- Verified
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 3,059
- Verified
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
Ferrero, J., Williams, L., Stella, H., Leitermann, K., Mikulskis, A., O'Gorman, J., & Sevigny, J. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 189
- Verified
A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder
Bolognani, F., del Valle Rubido, M., Squassante, L., Wandel, C., Derks, M., Murtagh, L., Sevigny, J., Khwaja, O., Umbricht, D., & Fontoura, P. (2019) · Science Translational Medicine
Autism Spectrum Disorder ResearchNeuroendocrine regulation and behavior
Cited by 128
- Verified
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2017) · Nature
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 83
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free